复方桂枝茯苓丸对脑缺血再灌注损伤大鼠NOS、Na^+-K^+-ATPase的影响  

Compound Guizhifuling Pill on NOS,Na^+-K^+-ATPase of Cerebral Ischemia-reperfusion Injury Rats

作　　者：张建荣[1] 任月朗 邢小燕[3] 

机构地区：[1]陕西中医学院,陕西西安712046 [2]西安北环医院,陕西西安710032 [3]咸阳职业技术学院医学系,西安咸阳712000

出　　处：《四川中医》2009年第4期13-15,共3页Journal of Sichuan of Traditional Chinese Medicine

摘　　要：目的:观察复方桂枝茯苓丸对脑缺血再灌注损伤(CRI)大鼠一氧化氮合酶(NOS)、Na+-K+-ATP酶(Na+-K+-ATPase)的影响。方法:用结扎双侧颈总动脉45min后再通法,制备CRI大鼠模型,用复方桂枝茯苓丸、血塞通治疗,给药2周,检测血清与脑匀浆NOS活性、脑匀浆Na+-K+-ATPase活性变化。结果:复方桂枝茯苓丸能降低CRI大鼠血清与脑匀浆NOS活性,升高大鼠脑匀浆Na+-K+-ATPase活性。结论:复方桂枝茯苓丸对CRI大鼠具有治疗作用。Objective： To investigate compound Guizhifuling pills on nitric oxide （NOS） and Na ＋ - K ＋ - ATPase of cerebral is-chemia- repeffusion injury （CRI） rats. Methods： CRI rat model was established by ligafion of bilateral carotid artery for 45 minutes. Rats were administered with compound Guizhifuling pills and Xuesaitong for 2 weeks. Then, changes of NOS and Na ＋ - K ＋ - ATPase activities in brain homogenate were observed. Results： Compound Guizhifuling pills reduced NOS activity in serum and brain homogenate of CRI rats, and increased Na^＋ - K^＋ - ATPase activities in brain homogenate of CRI rats. Conclusion： Compound Guizhifuling pill has certain therapeutic effect on CPd rats.

关 键 词：复方桂枝茯苓丸 CRI NOS NA^+-K^+-ATPASE 

分 类 号：R285.5[医药卫生—中药学]